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Insulin activates PI3-kinase (PI3K)/AKT to regulate
glucose homeostasis in the peripheral tissues and
the mediobasal hypothalamus (MBH) of rodents. We
report that insulin infusion into the MBH or dorsal
vagal complex (DVC) activated insulin receptors.
The same dose of insulin that activated MBH PI3K/
AKT did not in the DVC. DVC insulin instead activated
Erk1/2 and lowered glucose production in rats and
mice. Molecular and chemical inhibition of DVC
Erk1/2 negated, while activation of DVC Erk1/2 reca-
pitulated, the effects of DVC insulin. Circulating
insulin failed to inhibit glucose production when
DVC Erk1/2 was inhibited in normal rodents, while
DVC insulin action was disrupted in high-fat-fed
rodents. Activation of DVC ATP-sensitive potassium
channels was necessary for insulin-Erk1/2 and suffi-
cient to inhibit glucose production in normal and
high-fat-fed rodents. DVC is a site of insulin action
where insulin triggers Erk1/2 signaling to inhibit
glucose production and of insulin resistance in high-
fat feeding.
INTRODUCTION
Hepatic insulin resistance is a hallmark feature of diabetes
and obesity (Defronzo, 2009) and is defined as the inability
of insulin to inhibit hepatic glucose production, leading to a
dysregulation of glucose homeostasis. The inability of circu-
lating hyperinsulinemia to inhibit glucose production in obesity
and diabetes is due in part to a direct disruption of insulin
signaling cascades in the liver (Saltiel and Kahn, 2001). Recent
studies, however, implicate that insulin resistance in the MBH
leads to a dysregulation of glucose production and homeostasis
in diabetes and obesity as well (Gelling et al., 2006; Ono et al.,
2008).
In this regard, central administration of insulin is first docu-
mented to lower plasma glucose levels in normal dogs (Agarwala500 Cell Metabolism 16, 500–510, October 3, 2012 ª2012 Elsevier Inet al., 1977; Chowers et al., 1966), and this glucose-lowering
effect is abolished only when the liver is removed (Agarwala
et al., 1977). In parallel, direct infusion of insulin into the hypothal-
amus of normal rats lowers plasma glucose levels through an
inhibition of hepatic glucose production (Obici et al., 2002; Pocai
et al., 2005). Although the insulin signaling cascades in the
hypothalamus remain elusive, studies in rodents report that the
activation of the hypothalamic insulin receptor / PI3-kinase
(PI3K)/ ATP-sensitive potassium (KATP) channels signaling is
necessary for insulin to inhibit glucose production (Ko¨nner
et al., 2007a; Obici et al., 2002; Pocai et al., 2005). Importantly,
central delivery of insulin (Hallschmid et al., 2012; Filippi et al.,
2012) as well as activation of KATP channels in the brain (Kishore
et al., 2011) are implicated to lower plasma glucose levels and
glucose production in humans as well, although central insulin
regulates net hepatic glucose uptake rather than glucose pro-
duction in dogs (Ramnanan et al., 2011). Nonetheless, the signif-
icance of these findings as a whole is anchored when high-fat
feeding disrupts hypothalamic insulin signaling through the
activation of S6 kinase to inhibit glucose production (Ono
et al., 2008), while insulin injection triggers PI3K-AKT signaling
in the hypothalamus to lower glucose concentrations in uncon-
trolled diabetic rats (Gelling et al., 2006).
It is crucial to continue dissecting the hypothalamic insulin
signaling cascades that regulate peripheral metabolism. How-
ever, studies aiming to assess whether extra-hypothalamic
regions are sensitive to insulin to regulate glucose homeostasis
are equally important to potentially reveal signaling mechanisms
in the brain that mediate insulin action/resistance. DVC is an
extra-hypothalamic region that integrates nutritional and hor-
monal signals to regulate peripheral metabolism (Coll et al.,
2007; Cummings and Overduin, 2007; Grill, 2006; Morton
et al., 2005). In particular, a study reports that insulin injection
into the brainstem may inhibit food intake by decreasing the
expression of the Hap1-Ahi1 complex in mice (Niu et al., 2011),
but the potential impact of insulin on glucose regulation
remains unknown. In parallel, activation ofN-Methyl-d-aspartate
(NMDA) receptor in the DVC is sufficient (Lam et al., 2010a)
and necessary for nutrient sensing mechanisms in the gut
(Breen et al., 2012; Cheung et al., 2009; Wang et al., 2008) and
the hypothalamus (Lam et al., 2011) to inhibit glucose production
and regulate glucose homeostasis. These studies collectivelyc.
Figure 1. Insulin Signaling in the DVC
(A) Schematic representation of the working
hypothesis: Insulin action in the DVC and MBH
activates diverging signaling pathways that lead
to the activation of the KATP channels to inhibit
glucose production. The signaling cascade in-
volves MEK1/2/ERK1/2 in the DVC and PI3K in
the MBH.
(B–G) The indicated amounts of insulin were
infused for 5 min (0.2 ml/min) bilaterally into the
DVC of rats that were sacrificed after 30 min. The
level of phosphorylation of the IRb (B), Erk1/2 (C),
AKT (D, E), and IRS-1 (F, G) were analyzed by
western blot. The phosphorylation level was
quantified by densitometry and normalized for the
total protein. For each condition n = 4 samples
were analyzed. Data are presented as fold in-
crease over the saline-treated samples. A repre-
sentative blot for each protein is shown.
(H) The PI3K activity in both MBH and DVC tissues
upon insulin (0.2 ml/min for 5 min, 2 mU/site) stim-
ulation is shown. The PI3K (p85 subunit) was
immunoprecipitated from 500 mg of tissue and its
activity analyzed with the PI3K activity ELISA kit.
For each condition, n = 5 (DVC) or n = 6 (MBH)
rats were analyzed. Data are presented as fold
increase over the saline-treated samples. **p <
0.01, *p < 0.05 versus corresponding control.
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ways in the DVC to regulate glucose production and glucose
homeostasis.
Here, we assessed whether insulin infusion in the DVC acti-
vates the canonical PI3K-AKT signaling pathway or the alterna-
tive dual specificity kinase MAPK kinase (MEK1/2) pathway
that phosphorylates direct effectors Erk1 and Erk2. Using both
molecular and chemical gain- and loss-of-function approaches,
we then evaluated the glucoregulatory impact of the signaling
pathways activated by insulin in the DVC. Our findings unexpect-
edly illustrate that insulin triggers a PI3K-independent but MAP-Cell Metabolism 16, 500–510dependent pathway in the DVC to inhibit
glucose production (Figure 1A).
RESULTS
Insulin Signaling in the DVC
To first characterize the signaling path-
ways that are activated by insulin in the
DVC, insulin (2 mU/site; 0.2 ml/min for
5 min; analogous to MBH studies [Ono
et al., 2008]) was infused bilaterally into
the DVC, targeting the nucleus of the
solitary tract of conscious, unrestrained
rats. DVC wedges were than collected
after 5, 15, 30, 40, and 50 min. DVC
insulin activated insulin receptor (as-
sessed by phosphorylation of residue
Y1146 in the b subunit, Figures S1A and
S1B) but not AKT (assessed by phos-
phorylation of residue S473, Figure S1C)within 30–40 min of infusion. DVC insulin instead activated
Erk1/2 (assessed by phosphorylation of residue T202 and
residue Y204, Figure S1D) in the same time frame. In contrast
to the DVC, MBH insulin (2 mU/site) activated insulin receptor
(Figure S2A) and AKT (Figure S2B) but not Erk2 (Figure S2C).
Erk1 phosphorylation was elevated by 40 min (but not 30 min)
of MBH insulin infusion. These data indicate that insulin activates
its receptor in both MBH and DVC. However, the same dose of
insulin that activated downstream PI3K and AKT signaling in
the MBH did not activate PI3K/AKT in the DVC. DVC insulin
instead activated Erk1/2 signaling., October 3, 2012 ª2012 Elsevier Inc. 501
Figure 2. DVC Insulin Activates an Insulin Receptor-Erk1/2-Dependent but PI3K-Independent Pathway to Inhibit Glucose Production
(A) Experimental procedure and clamp protocol. Saline or insulin (a total of 2.52 mU, 1.26 mUper site) was infused at 0.006 ml/min during the clamp through the DVC
catheter. The insulin receptor antagonist (S961, 1.3 mg/ml), PI3K inhibitors (LY294002, 10 mMandwortmannin, 2 mM), and theMEK1/2 inhibitor (PD98059, 100 mM)
were preinfused at 0.006 ml/min for 1 hr before the clamp and then infused or coinfused with insulin during the clamp.
(B) Glucose infusion rate (mg/Kg/min) during the final 30 min of the clamp for the indicated treatment.
(C) Glucose production (mg/Kg/min) in basal (with square) and clamp (black square) conditions.
(D) Glucose uptake was comparable in all groups. Values are shown as mean + SEM; n = 6 for saline, insulin, and PD98059 + insulin treatments; n = 9 for S961 +
insulin; and n = 4 for LY294002 + insulin, wortmannin + insulin, and S961, PD98059, LY294002, and wortmannin alone treatments.
(E) A total of 4 mU (2 per site) of insulin were infused bilaterally into the DVC for 5 min (0.4 mU/min). The MEK1/2 inhibitor (PD98059, 200 mM) was preinfused at
0.2 ml/min for 5min and 1 hr before the insulin treatment, and then coinfusedwith insulin. The rats were then sacrificed after 30min. The level of phosphorylation of
the Erk1/2 was analyzed by western blot. The phosphorylation level was quantified by densitometry and normalized for the total protein. For each condition n = 5
sampleswere analyzed. Data are presented as fold increase over the saline-treated samples. A representative blot for each protein is shown. Values are shown as
mean + SEM. ***p < 0.001, **p < 0.01, *p < 0.05 versus corresponding control.
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insulin was infused into the DVC from 0.02 mU/site to 2 mU/site
(Figures 1B–1G). DVC wedges were obtained 30 min after
infusion. DVC insulin receptor was activated at 0.02, 0.2, and
2 mU/site and reached a peak at 20–200 mU/site (Figure 1B).
We then discovered DVC Erk1/2 activation followed a trend
similar to insulin receptor activation (Figure 1C). On the other
hand, DVC insulin did not significantly activate AKT (assessed
by the activatory phosphosite, S473, and T308) until reaching
20 mU/site (Figures 1D and 1E). In addition, we examined the
IRS-1 phosphorylation level, in particular focusing on two
phosphosites that lead specifically to the activation of Erk1/2
(Y895) and PI3K (Y608) (Figure 1G) (Sun and Liu, 2009). The
pattern of the phosphorylation of the Y895 on IRS-1 (Figure 1F)
directly reflected the response of Erk1/2 (Figure 1C), while the
phosphorylation of the Y608 similarly followed the pattern of
AKT activation (Figures 1D and 1E). Lastly, we measured PI3K
activity where we immunoprecipitated the PI3K from both
MBH and DVC wedges and measured the PIP3 production.
Consistent with the effect on AKT (Figures S1 and S2), MBH
but not DVC insulin infusion (2 mU/site) activated PI3K activity
(Figure 1H). These findings collectively indicate that DVC in-
sulin infused at 2 mU/site activated Erk1/2 but not PI3K-AKT
signaling.502 Cell Metabolism 16, 500–510, October 3, 2012 ª2012 Elsevier InInsulin Action in the DVC Lowers Glucose Production in
Rats and Mice
To address for a potential functional relevance of DVC insulin
signaling on glucose regulation independent of changes in
body weight (Table S1), insulin was first administered continu-
ously into the DVC (0.006 mU/min, a total of 1.26 mU/site; analo-
gous toMBH studies [Pocai et al., 2005]), targeting the nucleus of
the solitary tract, while changes in steady-state glucose kinetics
were assessed with the tracer-dilution methodology (Figure 2A).
To ensure that any changes in glucose kinetics were not due to
changes in circulating glucoregulatory hormones such as insulin
and glucagon, the rats underwent the pancreatic-euglycemic
clamps where plasma glucose and insulin levels were experi-
mentally maintained at basal level (Tables S2 and S3). During
the clamps, DVC insulin significantly increased the glucose infu-
sion rate required to prevent hypoglycemia (Figure 2B). The drop
in plasma glucose was due to an inhibition of glucose production
(Figure 2C and Figure S3), rather than changes in glucose uptake
(Figure 2D).
To evaluate whether DVC insulin also regulates glucose pro-
duction in mice, we repeated the infusion clamp experiments
in normal C57/B6 mice (Figure 3A). Mice underwent stereotactic
surgery for a single catheter implantation that targeted the fourth
ventricle as well as vascularization for infusion. Direct infusion ofc.
Figure 3. Intracerebroventricular (Fourth)
Infusion of Insulin Lowers Glucose Produc-
tion in Mice
(A) Experimental procedure and clamp protocol.
Saline or insulin (a total of 4 mU) was infused at
0.017 ml/min during the clamp through the ICV
(fourth) catheter.
(B) Glucose infusion rate (mg/Kg/min) measured
during the final 20 min of the clamp.
(C) Glucose production (mg/Kg/min) during the
clamp.
(D) Glucose uptake was comparable in all groups.
Values are shown as mean + SEM n = 8 mice per
group. *p < 0.05 versus corresponding control.
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creased the glucose infusion rate required to maintain euglyce-
mia (Figure 3B). Consistent with data obtained in rats, insulin
fourth ventricle inhibited glucose production (Figure 3C) but did
not affect glucose uptake (Figure 3D) in mice. Together, these
findings suggest that insulin action in the DVC inhibits glucose
production in rats and mice in vivo.
To evaluate whether insulin receptor activation in the DVC is
necessary for insulin action, an insulin receptor antagonist,
S961 (Scha¨ffer et al., 2008), was infused into the DVC in the
presence or absence of insulin. Of note, a previous study docu-
mented the effectiveness of using S961 in negating insulin
action in the ventromedial hypothalamus (Paranjape et al.,
2010). Coinfusion of S961 with insulin in the DVC negated the
ability of DVC insulin to increase glucose infusion rate (Figure 2B)
and lower glucose production (Figure 2C and Figure S3).
Glucose uptake was not affected (Figure 2D), and DVC S961
alone did not affect glucose metabolism (Figures 2B–2D and
Figure S3). Thus, insulin activates insulin receptor in the DVC
to lower glucose production.
Insulin Activates a DVC PI3K-Independent but Erk1/2-
Dependent Pathway to Inhibit Glucose Production
To evaluate whether PI3K signaling is necessary for DVC insulin
to inhibit glucose production, we coinfused DVC insulin with
either PI3K inhibitor LY 294002 or wortmannin (Figure 2A).
Neither of the PI3K inhibitors abolished the glucoregulatoryCell Metabolism 16, 500–510effect of DVC insulin (Figures 2B and
2C), consistent with the fact that DVC
insulin failed to activate PI3K-AKT sig-
naling when administered at a dose
(2 mU/site) similar to the clamp studies
(Figures 1D, 1E, 1G, and 1H). DVC PI3K
inhibitors alone did not affect glucose
metabolism (Figures 2B–2D).
The activation of the insulin receptor
by insulin also leads to the activation of
a MAPK-dependent signaling pathway
(Saltiel and Kahn, 2001), and DVC insulin
activated Erk1/2 signaling (Figure 1C
and Figure S1D). We next explored
whether DVC insulin triggers MAPK sig-
naling events to inhibit glucose produc-
tion. When we coinfused the MEK1/2inhibitorPD98059with insulin in theDVC, theability ofDVC insulin
to activate Erk1/2 (Figure 2E), increase glucose infusion rate (Fig-
ure 2B), and inhibit glucose production (Figure 2C) was negated.
Glucose uptake was unaltered (Figure 2D), and DVC PD98059
alone did not affect glucose metabolism (Figures 2B–2D).
To alternatively evaluate for the role of DVC Erk1/2 signaling,
an adenovirus expressing the dominant-negative form of MEK1
(MEK1-DN) was generated (Figure 4A). MEK1-DN negated
insulin-induced Erk1/2 activation in HEK293 cell line, while
insulin receptor and AKT activation were intact (Figure 4B).
Direct injection of MEK1-DN into the DVC also negated insulin-
induced Erk1/2 activation (Figure 4C). During the clamps, DVC
MEK1-DN reversed the ability of DVC insulin infusion to increase
glucose infusion rate (Figure 4D) and lower glucose production
(Figure 4E and Figure S4A) as compared to DVC GFP-injected
control rats. DVC MEK1-DN alone did not affect glucose regula-
tion (Figures 4D and 4E and Figure S4A), and glucose uptake re-
mained comparable among groups (Figure S4B).
We next activated DVC Erk1/2 signaling per se and evaluated
whether the metabolic effect of insulin is recapitulated. An ade-
novirus expressing the constitutively active form of MEK1
(MEK1-CA) was constructed (Figure 4A) and was found to acti-
vate Erk1/2 signaling in vitro (Figure 4B). Direct injection of
MEK1-CA into the DVC activated Erk1/2 signaling (Figure 4C)
and was sufficient to increase glucose infusion rate (Fig-
ure 4D) and lower glucose production (Figure 4E and Figure S4A)
during the clamps compared to DVC GFP-injected control rats., October 3, 2012 ª2012 Elsevier Inc. 503
Figure 4. Glucoregulatory Impact of MEK1 Dominant-Negative or Constitutively Active Overexpression in the DVC
(A) The MEK1 diagram is shown with highlighted point mutations that caused its inactivation (MK1-DN, D208A) or the activation (MEK1-CA, S218D, S222D).
(B) HEK293 cells were infected with an adenovirus expressing GFP or active/inactive MEK1. Forty-eight hours postinfection, cells were starved for 16 hr and then
treated with insulin (100 nM) for 30 min. Cell lysates were immunoblotted for phospho/total IRb, AKT, and Erk1/2 and total MEK1.
(C) The adenovirus expressing the MEK1-DN, MEK-CA, or GFP was injected the same day of the stereotactic surgery bilaterally into the DVC. On day 6, a total of
4 mU (2 per site) of insulin was infused for 5 min (0.4 mU/min). The rats were then sacrificed after 30 min. The level of phosphorylation of Erk1/2 was analyzed by
western blot. The phosphorylation level was quantified by densitometry and normalized for the total protein. For each condition, n = 5 samples were analyzed. A
representative blot is shown. Values are shown as mean + SEM.
(D and E) Pancreatic-euglycemic clamp. Saline or insulin (a total of 2.52 mU, 1.26 mU per site) was infused bilaterally into the DVC at 0.006 ml/min during the clamp
through the DVC catheter. (D) Glucose infusion rate (mg/Kg/min) measured during the final 30 min of clamp. (E) Glucose production (mg/Kg/min) in basal (with
square) and clamp (black square). Values are shown asmean + SEMn = 6GFP rats (untreated or insulin-treated), n = 6MEK1-CA rats, n = 7MEK1-DN rats treated
with insulin, and n = 4 MEK1-DN rats treated with saline. ***p < 0.001, **p < 0.01, *p < 0.05 versus corresponding control.
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egulatory impact of DVC MEK1-CA was comparable to that
seen with DVC insulin. Together with themolecular and chemical
loss-of-function data, these gain-of-function experiments tar-
geting DVC Erk1/2 signaling suggest that activation of Erk1/2
signaling in the DVC is sufficient and necessary for insulin to
inhibit glucose production.
DVC Insulin-Erk1/2 Signaling Activates KATP Channels
to Inhibit Glucose Production
To investigate the potential downstream effectors of insulin-
Erk1/2 signaling in the DVC, we first note that insulin activates
KATP channels in hippocampal neurons in an Erk1/2-dependent
and PI3K-independent manner in vitro (O’Malley et al., 2003).
In parallel, the Kir6.2 subunit of the KATP channels is phosphory-
lated by Erk1/2 at T341 and S385 in vitro (Lin and Chai, 2008).
Given that the Kir6.2 KATP channels are highly expressed in the
DVC of rat brains (Thomzig et al., 2005) and that activation of
the hypothalamic Sur1/Kir6.2 KATP channels is necessary for
insulin to inhibit glucose production (Pocai et al., 2005), we
next investigated whether activation of the KATP channels in
the DVC is necessary for insulin-Erk1/2 signaling to inhibit
glucose production. To address this possibility, KATP channel
blocker glibenclamide was coinfused with insulin into the DVC504 Cell Metabolism 16, 500–510, October 3, 2012 ª2012 Elsevier Inwhile the impact on glucose kinetics was assessed. Coinfusion
of glibenclamide with insulin negated the ability of DVC insulin
to increase glucose infusion rate (Figure 5A) and lower glucose
production (Figures 5B and 5C) with no changes in glucose
uptake (Figure 5D). We also inhibited DVC KATP channels in the
presence of direct Erk1/2 activation via MEK-CA. DVC MEK1-
CA failed to increase glucose infusion rate (Figure 5A) and lower
glucose production (Figures 5B and 5C) in the presence of DVC
glibenclamide infusion. DVC glibenclamide alone did not affect
glucose metabolism (Figures 5A–5D). Next, we administered
KATP channel opener diazoxide in the DVC and found that DVC
diazoxide increased glucose infusion rate (Figure 5A) and low-
ered glucose production (Figures 5B and 5C) with no changes
in glucose uptake (Figure 5D). Thus, activation of KATP channels
is necessary for DVC insulin-Erk1/2 signaling and sufficient to
inhibit glucose production.
Previous studies indicate that insulin potentiates NMDA
receptor transmission in the rat hippocampus (Christie et al.,
1999). Given that activation of NMDA receptor in the DVC is suffi-
cient (Lam et al., 2010a) and necessary for hypothalamic nutrient
sensing (Lam et al., 2011) to lower glucose production, these
studies raise the possibility that insulin alternatively activates
NMDA receptor in the DVC to regulate glucose metabolism.
We here inhibited the DVC NMDA receptor with MK801 in thec.
Figure 5. Activation of KATP Channels in
the DVC Is Necessary for Insulin and
MEK1-CA and Sufficient to Inhibit Glucose
Production
(A–D) A bilateral DVC catheter was implanted on
rats (260–280 g) on day 0. The adenovirus ex-
pressing the MEK-CA (pfu = 1.7 3 108) was in-
jected the same day at 3 ml per site. Venous and
arterial cannulations were performed on day 7,
and the pancreatic clamp protocol was performed
on day 11. Saline, insulin (a total of 2.52 mU,
1.26 mU per site), and diazoxide (46.3 mM) were
infused at 0.006 ml/min during the clamp through
the DVC catheter. The KATP channel inhibitor
(glibenclamide, 100 mM) was preinfused at
0.006 ml/min for 1 hr before the clamp and infused
alone, coinfused with insulin, or infused in MEK1-
CA rats during the clamp. Another group of MEK1-
CA rats received DVC saline infusion. (A) Glucose
infusion rate (mg/Kg/min) measured during the
clamp for the indicated treatment. (B) Glucose
production (mg/Kg/min) in basal (with square) and
clamp (black square) conditions for the indicated
treatments. (C) Glucose production suppression
(%) induced by the indicated treatments. (D)
Glucose uptake was comparable in all groups.
Values are shown as mean + SEM of n = 4–6 rats
per group. ***p < 0.001, **p < 0.01, *p < 0.05 versus
the corresponding controls.
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ability of DVC insulin to increase glucose infusion rate (Fig-
ure S5A) and lower glucose production (Figures S5B and S5C)
during the clamps, while glucose uptake remained unchanged
(Figure S5D). DVC MK801 alone did not affect glucose metabo-
lism (Figure S5).
These data collectively suggest that DVC insulin-Erk1/2 sig-
nals via a KATP channel-dependent and NMDA receptor-inde-
pendent pathway to inhibit glucose production.
Circulating Hyperinsulinemia Inhibits Glucose
Production through Erk1/2 Signaling in the DVC
To begin addressing the physiological role of DVC Erk1/2 sig-
naling in mediating insulin to regulate glucose homeostasis, we
inhibited MAPK-signaling cascades in the DVC while plasma
insulin levels were raised by3- to 4-fold (Table S3) via a 2 hr hy-
perinsulinemic-euglycemic clamp (Figure 6A). Circulating hyper-
insulinemia increased glucose infusion rate (Figure 6B) required
to maintain euglycemia (Table S1). This corresponded to an
inhibition of glucose production (Figures 6C and 6E) and a
stimulation of glucose uptake (Figure 6D). In the presence of
DVC Erk1/2 signaling inhibition (via PD98069), the glucose infu-
sion rate was reduced during the hyperinsulinemic-euglycemic
clamps (Figure 6B). The ability of insulin to stimulate glucose
uptake remained intact (Figure 6D) while the suppression of
glucose production was partly prevented (Figures 6C and 6E).
Thus, a direct disruption of Erk1/2 signaling in the DVC impairs
circulating hyperinsulinemia to inhibit glucose production and
may thereby lead to hepatic insulin resistance.CellHigh-Fat Feeding Induces Insulin Resistance in the DVC,
while DVC Insulin Resistance Is Bypassed by Direct
Activation of DVC KATP Channels
High-fat diet (HFD) feeding of rats induces hepatic insulin resis-
tance (Wang et al., 2001), due partly to a disruption of hypotha-
lamic insulin action (Ono et al., 2008). To test whether HFD
induces insulin resistance in extra-hypothalamic regions such
as the DVC, we fed rats with HFD for 3 days and first infused
insulin (2 mU/site) and analyzed the level of Erk1/2 activation in
the DVC (Figure 7A). We then tested the glucoregulatory effect
of DVC insulin in HFD rats via the use of the pancreatic clamp
(Figure 7B). Consistent with previous findings (Figure 1C and Fig-
ure S1D), DVC insulin activated Erk1/2 in normal rats, but instead
failed to activate Erk1/2 in HFD rats (Figure 7A). There was
a significant increase of basal DVC Erk2 activation in HFD-fed
rats, but DVC insulin did not further activate Erk2 (Figure 7A).
Importantly, the failure of DVC insulin to activate Erk1/2 signaling
was associated with the inability of DVC insulin infusion to
increase glucose infusion rate (Figure 7C) and lower glucose
production (Figure 7D and Figure S6B) during the clamps in
HFD rats with no changes in glucose uptake (Figure S6A).
However, when we tested whether activation of DVC Erk1/2
signaling could bypass insulin resistance by directly injecting
MEK1-CA into the DVC of HFD rats, DVC MEK1-CA failed to
lower glucose production (data not shown).
Lastly, given that activation of the KATP channels in the DVC is
necessary for insulin-Erk1/2 and sufficient to inhibit glucose
production in normal rats (Figure 5), we directly infused diazo-
xide into the DVC of HFD rats. DVC diazoxide increased glucoseMetabolism 16, 500–510, October 3, 2012 ª2012 Elsevier Inc. 505
Figure 6. Direct Disruption of ERK1/2
Signaling in the DVC Negates the Ability
of Circulating Insulin to Inhibit Glucose
Production
(A) Experimental procedure and hyperinsulinemic
clamp protocol. Saline or the MEK1/2 inhibitor
(PD98059, 100 mM) was preinfused at 0.006 ml/min
for 1 hr before the clamp and then during the
clamp at the same rate through the DVC catheter.
(B) Glucose infusion rate (mg/Kg/min) measured
during the 30 min of the clamp.
(C) Glucose production (mg/Kg/min) in basal (with
square) and clamp (black square) conditions.
(D) Glucose uptake was comparable in all groups.
(E) Glucose production suppression (%) induced
by the indicated treatments. Values are shown as
mean + SEM of n = 7 for both saline and PD98059
treatments. ***p < 0.001, **p < 0.01, *p < 0.05
versus corresponding control.
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ure 7D and Figure S6B) in HFD rats to a similar extent as in
normal rats (Figure 5). Together, these data suggest that ac-
tivation of DVC KATP channels, but not Erk1/2 signaling, is suffi-
cient to bypass insulin resistance to lower glucose production in
HFD rats.
DISCUSSION
The metabolic impact of insulin action in the brain has generated
considerable interest in recent decades. In rodents, insulin ac-
tion in the hypothalamus regulates peripheral glucose (Koch
et al., 2008; Ko¨nner et al., 2007b; Obici et al., 2002; Pocai
et al., 2005) and lipid (Scherer et al., 2011; Koch et al., 2008)
homeostasis, as well as food intake and body weight (Schwartz
and Porte, 2005). The clinical relevance of insulin action in the
brain is becoming apparent as intranasal delivery of insulin
reduces food intake and plasma glucose levels in normal
humans (Hallschmid et al., 2012; Filippi et al., 2012). Intranasal
insulin delivery does not limit site of insulin action to the hypo-
thalamus, suggesting that extra-hypothalamic sites remain pos-
sible targets for insulin. The current study reveals DVC as a
responsive region to insulin to regulate glucose production in
both rats and mice. Contrary to insulin action in the hypothal-
amus, insulin in the DVC triggers a PI3K-independent pathway
to regulate glucose production. Insulin infusion into the DVC fails
to activate PI3K and AKT, while the same dose of insulin is suffi-
cient to activate PI3K and AKT in the hypothalamus. In addition,
direct infusion of PI3K inhibitors into the DVC fails to negate the
glucoregulatory effect of insulin, while the same dose of inhibi-
tors given into the third ventricle is sufficient to abolish the effect
of central insulin. Although the insulin signaling pathway that506 Cell Metabolism 16, 500–510, October 3, 2012 ª2012 Elsevier Inc.mediates insulin’s ability to inhibit glu-
cose production in both the DVC and
MBH diverges, the downstream effector
appears to be the same as infusion of
the KATP channel blocker into the
DVC (like in MBH, Pocai et al., 2005)
abolishes the ability of insulin to inhibitglucose production. These findings imply that direct activation
of KATP channels in the brain, which lowers glucose production
in humans (Kishore et al., 2011), may not be limited to the KATP
channels expressed in the hypothalamus, but also the ones ex-
pressed in the DVC. Nonetheless, an important question remains
as to how DVC insulin activates KATP channel.
Consistentwith the fact that insulin activatesKATP channel in an
Erk1/2-dependentmanner in thehippocampal neurons (O’Malley
et al., 2003), DVC insulin administration activates Erk1/2 signaling
and KATP channels in association with an inhibition of glucose
production. Importantly, molecular and chemical inhibition of
Erk1/2 upstream kinase MEK1 negates the ability of DVC insulin
to activate Erk1/2 and inhibit glucoseproduction,whilemolecular
activation of MEK1 in the DVC is sufficient to recapitulate the
effect of insulin to activate Erk1/2 and KATP channels and inhibit
glucose production. Given that the activation of KATP channels
in the hypothalamus mediates not only insulin but also nutrients
to regulate glucose homeostasis (Lam, 2010b; Yue and Lam,
2012), the current findings raise the possibility that nutrient-
related signals activate DVC KATP channels to regulate glucose
homeostasis. This hypothesis remains to be tested. Although
the direct delivery of insulin into theDVC is potentially pharmaco-
logical in nature, the physiological relevance of insulin action in
the DVC is demonstrated when a direct disruption of DVC Erk1/
2 signaling negates the ability of circulating hyperinsulinemia to
inhibit glucose production. Together with the ability of the hypo-
thalamus to sense circulating insulin to regulate glucose produc-
tion, these data illustrate that insulin action in the DVC and the
MBH may exhibit redundant, but yet different, sensing mecha-
nisms to mediate insulin’s ability to inhibit glucose production.
To date, it is believed that the metabolic effect of insulin on
glucose regulation in insulin-sensitive tissues such as muscle,
Figure 7. HFD Induces Insulin Resistance in the DVC, while DVC Insulin Resistance Is Bypassed by Direct DVC KATP Channel Activation
(A) A bilateral DVC catheter was implanted on rats (260–280 g) on day 0. On day 3 the rats were put on HFD or RC, and on day 6, a total of 4 mU (2 per site) of insulin
was infused for 5 min (0.2 ml/min). The rats were then sacrificed after 30 min. The level of phosphorylation of Erk1/2 was analyzed by western blot. The phos-
phorylation level was quantified by densitometry and normalized for the total protein. For each condition at least n = 5 samples were analyzed. Data are presented
as fold increase over the RC saline-treated samples. A representative blot is also shown.
(B) Experimental procedure and clamp protocol of 3 days HFD-fed rats. Saline, insulin (a total of 2.52 mU, 1.26 mUper site), and diazoxide (46.3 mM)were infused at
0.006 ml/min during the clamp through the DVC catheter.
(C) Glucose infusion rate (mg/Kg/min) measured during the clamp.
(D) Glucose production during the clamp (mg/Kg/min). Values are shown as mean + SEM n = 4–6 rats for saline, insulin, and diazoxide treatments. **p < 0.01, *p <
0.05 versus corresponding control.
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Insulin Signaling in the Dorsal Vagal Complexadipocytes, liver, and the hypothalamus is mediated by a
PI3K-dependent and MAP-kinase-independent mechanisms
(Gabbay et al., 1996; Obici et al., 2002; Saltiel and Kahn,
2001). To our surprise, our findings contrarily illustrate that insulin
triggers an Erk1/2 signaling-dependent but PI3K-independent
mechanism in the DVC to activate KATP channels and inhibit
glucose production in vivo. Although the underlying preferential
mechanism(s) of insulin to activate MEK1/2 over PI3K in the
DVC remain to be clarified, we postulate that insulin in the DVC
activates Erk1/2 signaling to phosphorylate the Kir6.2 subunit
of the KATP channels at T341 and S385 (Lin and Chai, 2008)
and lowers glucose production. This working hypothesis re-
mains to be tested.
The DVC consists of various nuclei such as the nucleus of the
solitary tract (NTS), the area postrema, and the dorsal motor
nucleus of the vagus. Although our current DVC surgical proce-
dure targets the infusate to the NTS and suggests that insulin
action in the NTS lowers glucose production, future studies are
warranted to characterize and compare insulin signaling and
the associated metabolic impacts in each of the nuclei withinCellthe DVC. In addition, the role of the sympathetic and/or parasym-
pathetic output pathways that may mediate the ability of DVC
insulin to regulate glucose production remains to be clarified.
High-fat feeding induces insulin resistance at the level of
peripheral tissues as well as the hypothalamus. The current
study pinpoints insulin resistance in the DVC as an additional
site of signaling impairment induced by high-fat feeding. Inter-
estingly, in contrast to peripheral tissues and the hypothalamus,
where a disruption in PI3K activity is primarily responsible for
the inability of insulin to regulate glucose metabolism, high-fat
feeding impairs the ability of insulin to activate Erk1/2 signaling
in the DVC and inhibit glucose production. However, direct acti-
vation of Erk1/2 signaling in the DVC still fails to inhibit glucose
production in response to high-fat feeding, while DVC KATP
channel activation is equally potent in both normal and HFD
rats to inhibit glucose production. These findings indicate that
diet-induced DVC insulin resistance lies in the inability of Erk1/
2 signaling to activate KATP channels. In light of the fact that
direct activation of KATP channels in the DVC bypasses insulin
resistance to inhibit glucose production in high-fat-fed ratsMetabolism 16, 500–510, October 3, 2012 ª2012 Elsevier Inc. 507
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Insulin Signaling in the Dorsal Vagal Complex(current study), oral diazoxide treatment may be equally potent
to inhibit glucose production in normal humans (Kishore et al.,
2011) and in individuals with obesity and diabetes. This working
hypothesis remains to be tested.
In summary, we here unveil that insulin normally triggers
an Erk1/2-depenedent but PI3K-independent pathway in the
DVC to inhibit glucose production. Importantly, high-fat feed-
ing disrupts the insulin-Erk1/2 signaling axis in the DVC to
inhibit glucose production, thereby revealing a previously




Antibodies anti-IRb (total and p-Y1146), AKT (total, p-T308 and p-S473),
ERK1/2 (total and p-T202/Y204), IRS-1 (total and p-Y895), and MEK1 (total)
were fromCell Signaling Technology (Danvers, MA). The anti-p89 PI3K subunit
antibody and the anti-phospho-IRS-1 (p-Y608) antibodies were from Millipore
(Billerica, MA). The Pierce ECL Western Blotting Substrate was from Thermo
Scientific (Rockford, IL). Radioactive [3-3H]glucose was from PerkinElmer
(Boston, MA). Mutagenesis/PCR cloning primers were from ACGT Corp
(Wheeling, IL). The sequence analysis was performed by the TCAG
Sequencing Facility (Hospital for Sick Children, Toronto, ON). LY294002, wort-
mannin, PD98059, glibenclamide, diazoxide, and insulin were from Sigma-Al-
drich (St. Louis, MO). The cDNA for MEK1 was in a p-express clone from
Genome Club (BioScience imaGene). HEK293T cells were from the American
Type Culture Collection (ATCC).
Animal Preparation
Eight-week-old male Sprague-Dawley rats weighing between 260 and 280 g
and 18-week-old male C57/B6 mice weighing between 25 and 30 g (Charles
River Laboratories, Montreal, QC) were used for our studies. Rats and mice
were housed in individual cages andmaintained on a standard light-dark cycle
with access to standard rat/mice chow andwater ad libitum. Rats were stereo-
taxically (David Kopf Instruments, Tujunga, CA) implanted with indwelling
bilateral catheters targeting the mediobasal hypothalamus (MBH) (3.1 mm
posterior of bregma, 0.4 mm lateral from midline, and 9.6 mm below skull
surface) (Lam et al., 2011) and the nucleus of the solitary tract (NTS) within
the DVC (0.0 mm on occipital crest, 0.4 mm lateral to midline, and 7.9 mm
below skull surface) (Lam et al., 2010a). After 1 week of recovery, rats under-
went intravenous catheterization where the internal jugular vein and carotid
artery were catheterized for infusion and sampling. Mice were stereotaxically
(David Kopf Instruments) implanted with indwelling catheters in the fourth
ventricle (6 mm posterior of bregma and 4 mm below the skull). After a week
of recovery, mice underwent intravenous catheterization where the internal
jugular vein was catheterized for infusion. All study protocols were reviewed
and approved by the Institutional Animal Care and Use Committee of the
University Health Network.
DVC/MBH Infusion for Signaling Study
A bilateral DVC or MBH catheter was implanted on day 0 on male Sprague-
Dawley rats (260–280 g) as described above. On day 5, the rats were
restricted to 15 g (50.7 cal for RC and 77.1 cal for HFD) of food for the
night, and on day 6, a total of 4 mU (2 per site) of insulin (Ono et al.,
2008) was infused for 5 min (0.4 mU/min). The MEK1/2 inhibitor (PD98059,
200 mM) was preinfused at 0.2 ml/min for 5 min and 1 hr before the insulin
treatment, and then coinfused with insulin. The rats were then sacrificed
after 30 or 40 min, and the DVC or MBH tissue was immediately collected.
Tissues (12 mg) were lysed with a handheld glass homogenizer in a buffer
containing 50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1 mM EDTA, 1% (w/v)
Nonidet P40, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 5 mM
sodium pyrophosphate, 0.27 M sucrose, 1 mM Dithiotritolo (DTT), and pro-
tease inhibitor cocktail (Roche). Protein concentration of each homogenized
tissue was determined with the Pierce 660 nm protein assay (Thermo
Scientific).508 Cell Metabolism 16, 500–510, October 3, 2012 ª2012 Elsevier InWestern Blotting
Between 10 and 20 mg of tissue lysates obtained as described above were
subjected to electrophoresis on a 10% polyacrylamide gel and transferred
to nitrocellulose membranes. The membranes were incubated for 1 hr with
TBS-T containing 5% (w/v) BSA. The membranes were then immunoblotted
in the same buffer for 16 hr at 4Cwith the indicated primary antibodies diluted
to 1000-fold. The blots were thenwashed four times with TBS-T and incubated
with secondary HRP-conjugated antibodies in 5% skimmed milk. After
repeating the washing steps, the signal was detected with the enhanced
chemiluminescence reagent (ECL). Immunoblots were developed using a
film automatic processor (SRX-101; Konica Minolta Medical), and films were
scanned with 300 dpi resolution on a scanner (PowerLook 1000; UMAX).
The phosphorylation level of the Irb, AKT, IRS-1, and Erk1/2 was quantified
by densitometry with the ImageJ software and normalized for the correspond-
ing total protein level.
PI3K Activity Assay
The activity of the MBH/DVC PI3K was measured with the PI3K activity ELISA:
Pico kit (echelon, K-1000s; Salt Lake City, UT). Briefly, the PI3K was immuno-
precipitated from 500 mg of the tissue lysate produced upon DVC/MBH
infusion (as described above) with 5 ml of an anti-p89 PI3K subunit antibody
(Millipore). The lysate was incubated for 1 hr at 4C in a rotating wheel with
the antibody, and then 25 ml of 25% protein A/G beads were added (Santa
Cruz) and the lysate was incubated for an additional hour at 4C in a rotating
wheel. The beads were then washed three times with the lysis buffer (see
above) + 0.1M NaCl; three times with 0.1 M Tris-HCl (pH 7.4), 5 mM LiCl,
and 0.1 mM sodium orthovanadate; and twice with 10 mM Tris-HCl (pH 7.4),
150 mM NaCl, 5 mM EDTA, and 0.1 mM sodium orthovanadate. The beads
were then resuspended in the KBZ reaction buffer provided by the kit. The
Production of PI(3,4,5)P2 was measured according to the manufacturer
instructions. Data are presented as fold increase over the saline-treated
samples. Values are shown as mean + SEM significant with a p value of <
0.05 versus corresponding control.
DVC Infusion and Pancreatic-Euglycemic/Hyperinsulinemic Clamp
in Rats
Four days after intravenous catheterization, animals whose food intake and
body weight had recovered back to within 10% of baseline underwent the
clamp studies. Rats were restricted to 15 g (50.7 cal for RC and 77.1 cal for
HFD) of food the night before the experiment to ensure the same nutritional
status during the clamps, which lasted 210 min. Saline, insulin (a total of
1.26 mU per site), or the KATP channel activator (diaxozide, 56 pmols per site)
were infused at 0.006 ml/min during the clamp (from time 0 to 210) through
the DVC catheter. The insulin receptor antagonist (S961, 1.3 mg/ml) (Scha¨ffer
et al., 2008; Paranjape et al., 2010), the PI3K inhibitors (LY294002, 16.2 pmols
per site and wortmannin, 3.2 pmols per site), the MEK1/2 inhibitor (PD98059,
0.156 nmols per site), and the KATP channel inhibitor (glibenclamide,
0.156 nmols per site) were preinfused at 0.006 ml/min for 1 hr before the clamp
(time 60) and infused or coinfused with insulin during the clamp. A primed-
continuous intravenous infusion of [3-3H]glucose (40 mCi bolus, 0.4 mCi/min)
was also initiated at 0 min and maintained throughout the study to assess
glucose kinetics. A pancreatic (basal insulin)-euglycemic clamp was started
at time 90 min until 210 min. Somatostatin (3 mg/kg/min) was infused intrave-
nously along with insulin (1.2 mU/kg/min) to replace insulin back to basal. A
25%glucose solution was started at time 90 and periodically adjusted tomain-
tain plasma glucose levels. For the hyperinsulinemic clamp, insulin was intra-
venously infused at 4 mU/Kg/min. Samples for the determination of [3-3H]
glucose-specific activity and insulin (see Tables S1 and S2) levels were ob-
tained at 10 min intervals. At the end, the rats were sacrificed and samples
of MBH and DVC tissue were taken as previously reported (Lam et al.,
2011). The brain insulin and PI3K or MEK1/2 inhibitor concentrations were
chosen as previously described (Obici et al., 2002), while the concentration
of the glibenclamide and diazoxide was the same as previously reported
(Pocai et al., 2005).
Fourth Ventricle Infusion and Pancreatic-Euglycemic Clamp in Mice
A cannula was implanted in the fourth ventricle of male mice on day 0, and
venous and arterial cannulations were performed on day 7. The pancreaticc.
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Insulin Signaling in the Dorsal Vagal Complexclamp was performed on day 9. Saline or insulin (4.08 mU total) was preinfused
at 0.017 ml/min for 1 h 30 min before the clamp and then during the clamp
through catheters. A primed-continuous intravenous infusion of [3-3H]glucose
(1 mCi bolus, 0.1 mCi/min; Perkin Elmer) was also initiated at 0 min and
maintained throughout the study to assess glucose kinetics. A pancreatic
(basal insulin)-euglycemic clamp was started at time 60 min until 150 min.
Somatostatin (8.3 mg/kg/min) was infused along with insulin (1.4 mU/kg/min)
to replace insulin back to basal. A 10% glucose solution was started at time
60 and periodically adjusted to maintain plasma glucose levels. Samples for
the determination of [3-3H]glucose-specific activity were obtained at 10 min
intervals.
Preparation and Injection of MEK1 Dominant-Negative and
Constitutively Active Adenovirus in Rats
Rat MEK1 cDNA wild-type was mutated in the magnesium binding site (D208
mutated to A) to kill the catalytic activity (MEK1-DN) and in the two activatory
serines (S218 and S222 mutated to D) to enhance the catalytic activity (MEK1-
CA). Cloning, restriction enzyme digests, DNA ligations, and other recom-
binant DNA procedures were performed using standard protocols. All
site-directed mutagenesis reactions were performed using KOD polymerase
(Novagen) followed by digestion of the product with DpnI. Mutated cDNA
was subcloned in the pacAd5 CMV shuttle vector of the RAPAd CMV Adeno-
viral Expression System (Cell Biolabs, Inc., San Diego, CA). The adenovirus
was produced in HEK293 cells by cotransfecting the PAC1 linearized RAPAd
Ad Backbone vector with the pacAd5 CMV shuttle vector carrying the cDNA
forMEK1-DNorMEK-CA orGFP according to themanufacturer’s instructions.
Purified adenoviruses with pfu of 1.83 108 (MEK1-DN), 1.73 108 (MEK1-CA),
or 3 3 108 (GFP) were injected the same day of the DVC brain surgery at 3 ml
per site.
HEK293 Viral Infection and Insulin Treatment
A total of 1 3 106 HEK293 cells were plated in a 6-well plate and infected the
day after with an adenovirus expressing GFP or active/inactive MEK1. Forty-
eight hours postinfection, cells were starved for 16 hr and then treated with
insulin (100 nM) for 30 min. Cells were then lysed in a buffer containing
50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1 mM EDTA, 1% (w/v) Nonidet P40,
1mMsodiumorthovanadate, 50mMsodium fluoride, 5mMsodium pyrophos-
phate, 0.27 M sucrose, 1 mMDithiotritolo (DTT), and protease inhibitor cocktail
(Roche). Twenty micrograms of lysates were immunoblotted for phospho/total
IRb, AKT, and Erk1/2 and total MEK1 (as described above).
Biochemical Analysis
Plasma glucose concentrations were measured by the glucose oxidase
method (Glucose Analyzer GM9; Analox Instruments, Lunenbertg, MA).
Plasma insulin levels were determined by radioimmunoassay (RIA) (Linco
Research, St. Charles, MO).
Statistical Analysis
Statistical analysis was done with GraphPad Prism by one-way ANOVA to
compare across the groups, followed by a Tukey’s post hoc test or t test where
appropriate to compare between groups. Statistical analysis was accepted as
significant with a p value of < 0.05. Data are presented as means + SEM.
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